Alzheimer’s Therapeutics Market Size, share 2021 – Industry Leading Player Update, Demand and Development Status, Analytical Overview, Regional Analysis and Forecast to 2030

In a recent published report, Kenneth Research has updated the market report for Alzheimers therapeutics Market for 2021 till 2030. Report further now discusses; the various strategies to be adopted or being adopted by the business players across the globe at various levels in the value chain. In the view of the global economic slowdown, we further estimated that China, India, Japan and South Korea to recover fastest amongst all the countries in the Asian market. Germany, France, Italy, Spain to take the worst hit and this hit is expected to be regain 25% by the end of 2021- Positive Growth in the economic demand and supply.

U.S. Market recovers fast; In a release on May 4th 2021, the U.S. Bureau and Economic Analsysis and U.S. Census Bureau mentions the recovery in the U.S. International trade in March 2021. Exports in the country reached $200 billion, up by $12.4  billion in Feb 2021. Following the continuous incremental trend, imports tallied at $274.5 billion, picked up by $16.4 billion in Feb 2021. However, as COVID19 still haunts the economies across the globe, year-over-year (y-o-y) avergae exports in the U.S. declined by $7.0 billion from March 2020 till March 2021 whilest imports increased by $20.7 billion during the same time. This definitely shows how the market is trying to recover back and this will have a direct impact on the Healthcare/ICT/Chemical industries, creating a huge demand for Alzheimers therapeutics Market products.

Request To Download Sample of This Strategic Report:

Moreover, the median health expenditure per capita recorded in the high-income, upper-middle income, and low & lower-middle income countries, recorded to be over USD 2,000, USD 400, and USD 100 respectively. Additionally, in the same year, the spending on health in high-income countries and in the low- and middle-income countries comprised approximately 8.2% and 6.3% of the GDP respectively.

Global Alzheimer’s Therapeutics Market – Drivers, Restraints, Opportunities, Trends, and Forecast up to 2025
[75 pages report] This market research report includes a detailed segmentation of the global Alzheimer’s Therapeutics market by molecule type (Cholinesterase Inhibitors, NMDA Receptor Antagonists, and Others), by distribution channel (Hospital Pharmacies, Retail Pharmacies, and E Pharmacies), by region (North America, Europe, Asia Pacific, and Rest of the World).

Overview of the Global Alzheimer’s Therapeutics Market
Kenneth’s market research report predicts that the “Global Alzheimer’s Therapeutics Market” will grow at a CAGR of ~7.0% during the forecast period. The market has witnessed steady growth in the past few years and is sustaining due to an increase in geriatric population and promising pipeline in development.

Estimates are diverse, but specialists indicate that up to 5.5 million Americans aged 65 and above could have Alzheimer’s disease. Increase in geriatric population and promising pipeline in development is anticipated to boost the market growth. Emerging novel diagnostic technologies and investment in biomarkers for drug development are providing an opportunity for the development of the market. However, failures of late-stage drugs and restricted awareness about Alzheimer’s disease are hampering the market growth.

The majority of the revenue is generated from the leading players in the market with dominating sales of Eisai Co. Ltd, Novartis AG, Pfizer Inc., Eli Lilly & Company, Johnson & Johnson, Daiichi Sankyo Company Limited, F. Hoffmann-La Roche , H. Lundbeck A/S, TauRx Therapeutics Ltd, and Allergan.

According to the analysis, North America accounted for the largest share of the global Alzheimer’s therapeutics market in 2018. The Asia Pacific region is expected to witness the fastest growth rate due to the large patient pool and rising healthcare expenditure.

Request Free Sample Copy :-

By Molecule Type:
*Cholinesterase Inhibitors
*NMDA Receptor Antagonists
In 2018, the largest share among the molecule types used for the treatment of Alzheimer’s disease are cholinesterase inhibitors. This may also improve signs of neuropsychiatry such as depression or agitation.

By End Users:
*Hospital Pharmacies
*Retail Pharmacies

E-Pharmacies are increasingly adapted in many countries due to convenience and flexible accessibility.
By Regions:
*North America

North America is dominant in the global Alzheimer’s therapeutics market in 2018. The significant share of the North American region comes from US which is due to the accessibility to good quality healthcare and good reimbursement facilities.

Alzheimer’s Therapeutics Market Research Competitive Analysis – The Federal Government has led study initiatives on Alzheimer’s disease by the National Institute for Aging (NIA) at National Institutes for Health (NIH). Diverse variety of research is carried out through NIA-supported Alzheimer Research Centers across the US, which includes study of the causes, diagnosis and treatment, and management of the disease. NIA also supports the Alzheimer Clinical Trials Consortium which is intended to speed up and grow Alzheimer and associated dementia research and therapies. The NIH donated about $589 million in 2015 to AD study initiatives, which includes the Alzheimer’s Association, the National Health Institute (NIH), and the Federal Ministry of Health.

Key Vendors:
*Eisai Co. Ltd.
*Novartis AG
*Pfizer Inc.
*Eli Lilly & Company
*Johnson & Johnson

Key Competitive Facts
*Leading products like Aricept, Exelon, and Reminyl dominate the industry; Aricept with a cholinesterase inhibitor as its active component has the biggest business share in it.
*There is an increase in combination therapy recommended to the patients with Alzheimer’s disease.

Benefits – The report provides complete details about the sub-segments of the Alzheimer’s therapeutics market. Through this report, the key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, and government initiatives towards disease management in the upcoming years along with details of the existing pureplay companies and new players entering the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders in order to expand their business and capture the revenue in specific verticals and to analyze before investing or expanding the business in this market.

Request To Download Sample of This Strategic Report:

Key Takeaways:
*Understanding the potential market opportunity with precise market size and forecast data.
*A detailed market analysis focusing on the growth of Alzheimer’s therapeutics industry.
*Factors influencing the growth of the Alzheimer’s therapeutics market.
*In-depth competitive analysis of dominant and pure-play vendors.
*Prediction analysis of the Alzheimer’s therapeutics market in both developed and developing regions.
*Key insights related to major segments of the Alzheimer’s therapeutics market.
*Latest market trend analysis impacting the buying behavior of consumers.

Table of Contents
1 Industry Outlook
1.1 Industry Overview
1.1.1 Global Driver for Pharmaceutical Demand
1.1.2 Pharmaceutical Spending Region Wise
1.1.3 R&D Pipeline in Pharmaceutical Industry
1.1.4 Top Pharma Drugs by Sales in 2017 ($Million)
1.2 Total Addressable Market
2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 Market Snapshot
3.1 Market Definition – Infoholic Research 3.2 Segmented Addressable Market (SAM)
3.3 Industry Trends
3.4 Related Markets
3.4.1 Parkinson’s Disease
4 Market Outlook
4.1 Market Segmentation
4.2 Porter 5 (Five) Forces
5 Market Characteristics
5.1 Market Dynamics
5.1.1 Drivers Promising pipeline in development Increase in geriatric population
5.1.2 Restraints Failures of late-stage drugs Restricted awareness about Alzheimer’s disease
5.1.3 Opportunities Emerging novel diagnostic technologies Investment in biomarkers for drug development
5.1.4 DRO – Impact Analysis
5.2 Key Stakeholders
6 Molecule Type: Market Size and Analysis
6.1 Overview
6.2 Cholinesterase Inhibitors
6.3 NMDA Receptor Antagonists
6.4 Others
7 Distribution Channel: Market Size and Analysis
7.1 Overview
7.2 Hospital Pharmacies
7.3 Retail Pharmacies
7.4 E Pharmacies
8 Regions: Market Size and Analysis
8.1 Overview
8.2 North America
8.3 Europe
8.4 Asia Pacific

Request To Download Sample of This Strategic Report:

About Kenneth Research

Kenneth Research is a reselling agency providing market research solutions in different verticals such as Automotive and Transportation, Chemicals and Materials, Healthcare, Food & Beverage and Consumer Packaged Goods, Semiconductors, Electronics & ICT, Packaging, and Others. Our portfolio includes set of market research insights such as market sizing and market forecasting, market share analysis and key positioning of the players (manufacturers, deals and distributors, etc), understanding the competitive landscape and their business at a ground level and many more. Our research experts deliver the offerings efficiently and effectively within a stipulated time. The market study provided by Kenneth Research helps the Industry veterans/investors to think and to act wisely in their overall strategy formulation

Contact Us

Kenneth Research
Email: [email protected]
Phone: +1-(347)-627-0064

————————New Related Reports——————————

Indian In Vitro Diagnostics (IVD) Market

Hemmeter Market

Wound Care Solutions Market

Magnetic Resonance Imaging Market

Dialysis Market

Hemostats Market

Fetal and Neonatal Equipment Market

Security Operations Center Market

Immunotherapy Drugs Market

Medical Tourism Market

Christophe Rude
Christophe Rude
Articles: 15880